Panobinostat (Standard)

Panobinostat (Standard) (LBH589 (Standard) ) is the analytical standard of Panobinostat (HY-10224) . This product is intended for research and analytical applications. Panobinostat is a potent and orally active non-selective HDAC inhibitor, and has antineoplastic activities[1][2]. Panobinostat induces HIV-1 virus production even at low concentration range 8-31 nM, stimulates HIV-1 expression in latently infected cells[4]. Panobinostat induces cell apoptosis and autophagy. Panobinostat can be used for the study of refractory or relapsed multiple myeloma[3].

Product Specifications

CAS Number

[404950-80-7]

Product Name Alternative

LBH589 (Standard) ; NVP-LBH589 (Standard)

UNSPSC

12352005

Hazard Statement

H301+H331, H315, H318, H360, H373

Target

Apoptosis; Autophagy; HDAC; HIV; Reference Standards

Related Pathways

Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; Others

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Purity

98.09

Smiles

ONC(/C=C/C(C=C1)=CC=C1CNCCC2=C(C)NC3=CC=CC=C23)=O

Molecular Formula

C21H23N3O2

Molecular Weight

349.43

Precautions

H301+H331, H315, H318, H360, H373

References & Citations

[1]Scuto A, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008 May 15;111 (10) :5093-100.|[2]Crisanti MC, et al. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther. 2009 Aug;8 (8) :2221-31. |[3]Ocio EM, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010 May;95 (5) :794-803.|[4]Barton K, et al. Broad activation of latent HIV-1 in vivo. Nat Commun. 2016;7:12731. Published 2016 Sep 8.